Literature DB >> 8698098

The use of cyclophosphamide as an enhancer of the vaccine against foot-and-mouth disease.

E L Portiansky1, P H González, R P Laguens.   

Abstract

The immunization of biungulate animals with killed foot-and-mouth disease virus (FMDV) requires periodic vaccinations due to a low vaccine immunogenicity. Therefore, FMDV antigens need to be combined with adjuvants such as aluminium hydroxide, saponin or oil emulsions. Animal handling for periodic inoculations, and the repeated doses of vaccines that have to be administered increase the commercialization costs. Moreover, the use of adjuvants may induce adverse effects. In the present work we show that it is possible to increase the life span of neutralizing antibodies in serum when a single dose of cyclophosphamide (Cy) is administered four days before vaccination with aluminium hydroxidesaponin FMDV vaccine.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8698098     DOI: 10.1007/bf01969738

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  17 in total

1.  Immune modulating effects of low doses of cyclophosphamide and keyhole limpet hemocyanin on peripheral blood immune parameters in patients with metastatic renal cell carcinoma.

Authors:  S Kleinknecht; K H Bichler; W L Strohmaier
Journal:  Urol Int       Date:  1992       Impact factor: 2.089

2.  Protective and immunostimulating activity of a low dose of cyclophosphamide in the experimental infection of mice with foot-and-mouth disease virus.

Authors:  E L Portiansky; W M DiGirolamo; R P Laguens
Journal:  Experientia       Date:  1989-01-15

3.  Production and in vivo use of recombinant ovine IL-1 beta as an immunological adjuvant.

Authors:  A E Andrews; S A Lofthouse; V M Bowles; M R Brandon; A D Nash
Journal:  Vaccine       Date:  1994-01       Impact factor: 3.641

4.  Biodegradable microspheres as controlled-release tetanus toxoid delivery systems.

Authors:  M J Alonso; R K Gupta; C Min; G R Siber; R Langer
Journal:  Vaccine       Date:  1994-03       Impact factor: 3.641

5.  Immunosuppression in goats by dexamethasone and cyclophosphamide.

Authors:  G Koptopoulos; M Papanastasopoulou; S Lekkas; G Skaragas; O Papadopoulos
Journal:  Comp Immunol Microbiol Infect Dis       Date:  1992-10       Impact factor: 2.268

Review 6.  [Aluminum as an adjuvant in vaccines and post-vaccine reactions].

Authors:  M Fiejka; J Aleksandrowicz
Journal:  Rocz Panstw Zakl Hig       Date:  1993

7.  [Aluminum osteopathy--experience with therapy].

Authors:  S Sulková
Journal:  Vnitr Lek       Date:  1993-05

8.  Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.

Authors:  S M Lichtman; M J Ratain; D A Van Echo; G Rosner; M J Egorin; D R Budman; N J Vogelzang; L Norton; R L Schilsky
Journal:  J Natl Cancer Inst       Date:  1993-08-18       Impact factor: 13.506

9.  The biological effects of immunosuppression on cellular immunotherapy.

Authors:  D D Schoof; A F Massaro; J A Obando; J C Kusack; T J Eberlein
Journal:  Surg Oncol       Date:  1992-02       Impact factor: 3.279

10.  Further studies on the adjuvanticity of stearyl tyrosine and ester analogues.

Authors:  C L Penney; D Ethier; G Dionne; A Nixon-George; H Zaghouani; F Michon; H Jennings; C A Bona
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.